Niagen Bioscience, Inc. has announced the sale of its ChromaDex Reference Standards business to LGC in an all-cash transaction completed on February 24, 2026. The move allows Niagen Bioscience to streamline operations and sharpen its focus on NAD+ science and healthy aging innovation.
The divestiture marks a strategic step in the company’s plan to exit non-core activities. As a result, Niagen Bioscience will concentrate resources on advancing its intellectual property portfolio, expanding commercial growth, and strengthening its leadership in the longevity sector.
Strategic Shift Toward NAD+ Science
By completing the Niagen Bioscience sale of its reference standards unit, the company reinforces its commitment to NAD+ (nicotinamide adenine dinucleotide) research. Furthermore, the transaction supports its mission to deliver clinically validated and patented Niagen® solutions across consumer and clinical markets.
Rob Fried, CEO of Niagen Bioscience, stated that the decision reflects a disciplined approach to capital allocation. He emphasized that the company will continue investing in high-impact opportunities centered on NAD+ science and innovation. Therefore, this sale positions the business for more focused long-term growth.
LGC Expands Analytical Standards Portfolio
LGC Standards, a division of LGC Group, strengthens its global reference materials offering through this acquisition. The ChromaDex standards portfolio enhances LGC’s ability to serve pharmaceutical companies, food producers, and testing laboratories.
Bruno Rossi, EVP & GM of LGC Standards, noted that the acquisition expands the company’s North American commercial reach. In addition, it reinforces LGC’s role in supporting accurate testing and reliable analytical data across global supply chains.
Strengthening Core Business Focus
Overall, the Niagen Bioscience sale reflects a broader strategy to simplify operations while doubling down on core scientific expertise. By reallocating capital and talent toward NAD+ research and commercialization, the company aims to accelerate innovation in the longevity industry.
As the healthy aging market continues to grow, Niagen Bioscience is positioning itself to lead with science-backed solutions and focused operational execution.
